- CUSHR Faculty
- CU-GHS Partnership
- Healthy SC
- Make a Gift
- Contact Us
When it comes to health research, improving patient outcomes and health delivery are critical goals. That’s why researchers across the nation are increasingly focused on translational research – research that applies scientific breakthroughs in actual medical practice to improve patient care and health outcomes.
A group of health researchers at Clemson University, in partnership with clinical experts at the Greenville Health System (GHS) and the Medical University of South Carolina (MUSC), have joined together to launch an innovative, translational research initiative: South Carolina Translational Research Improving Musculoskeletal Health (SC-TRIMH).
Musculoskeletal disease has debilitating effects on the population which results in chronic pain, increased mortality, decreased mobility, and serious psychological effects. Such disorders among aging individuals are of particular concern, as the number of Americans over the age of 65 is predicted to double by 2030 – resulting in increased stress for the healthcare system.
Led by Professor Hai Yao, the SC-TRIMH initiative will leverage the resources of the Clemson University School of Health Research (CUSHR), Clemson University Biomedical Engineering Innovation Campus (CUBEInC), Greenville Health System (GHS), and the Medical University of South Carolina (MUSC), in order to address the challenges of bone and joint diseases. New methods of virtual modeling, cluster computing, and fabrication technologies will help design a new generation of devices and interventions that can both improve musculoskeletal health and reduce healthcare costs.
This unique initiative is anchored within CUSHR, providing opportunities for health research collaboration across colleges and departments and with health delivery system partners. A Clinical Advisory Group facilitates and advises the work of junior investigators and core research teams.
From left to right: Fei Peng, Hugo Sanabria, Will Richardson, Tong Ye
The goal of NIH R35 Maximizing Investigator’s Research Award (MIRA) is to increase the efficiency of NIGMS funding by providing investigators with greater stability and flexibility, thereby enhancing scientific productivity and the chances for important breakthroughs. The program will also help distribute funding more widely among the nation's highly talented and promising investigators. MIRA grants will generally be for 5 years (R01 equivalent), for both established investigators and new and early stage investigators.
This is a true testament to our mentoring and the development of our junior investigators in the SC-TRIMH program. Dr. Ding’s R35 award will support him to develop a multiscale computational model to uncover the structure, dynamics, and function relationship of osteoclast-specific V-ATPases and bone resorption for preventing osteoporosis.